Department of Rheumatology, Institute of Medicine, University of Debrecen Medical and Health Sciences Center, 98, Nagyerdei street, Debrecen, H-4032, Hungary.
Joint Bone Spine. 2010 Jan;77(1):13-9. doi: 10.1016/j.jbspin.2009.05.011. Epub 2009 Dec 21.
Angiogenesis is the formation of new capillaries from pre-existing vessels. A number of soluble and cell-bound factors may stimulate neovascularization. The perpetuation of angiogenesis involving numerous soluble and cell surface-bound mediators has been associated with rheumatoid arthritis (RA). These angiogenic mediators, among others, include growth factors, primarily vascular endothelial growth factor (VEGF) and hypoxia-inducible factors (HIFs), as well as pro-inflammatory cytokines, various chemokines, cell adhesion molecules, proteases and others. Among the several potential angiogenesis inhibitors, targeting of VEGF, HIF-1, angiopoietin and the alpha(V)beta(3) integrin, as well as some endogenous or synthetic compounds including angiostatin, endostatin, paclitaxel, fumagillin analogues, 2-methoxyestradiol and thalidomide seems to be promising for the management of synovial inflammation and angiogenesis. A complete review of antiangiogenic drugs used in animal models of arthritis or human RA is available in a table.
血管生成是指从预先存在的血管中形成新的毛细血管。许多可溶性和细胞结合的因子可能刺激新血管生成。涉及许多可溶性和细胞表面结合的介质的血管生成的持续存在与类风湿关节炎 (RA) 有关。这些血管生成介质，除其他外，包括生长因子，主要是血管内皮生长因子 (VEGF) 和缺氧诱导因子 (HIFs)，以及促炎细胞因子、各种趋化因子、细胞粘附分子、蛋白酶等。在几种潜在的血管生成抑制剂中，针对 VEGF、HIF-1、血管生成素和α(V)β(3)整联蛋白，以及一些内源性或合成化合物，包括血管抑素、内皮抑素、紫杉醇、沙利度胺、2-甲氧基雌二醇，似乎在治疗滑膜炎症和血管生成方面有希望。在关节炎或人类 RA 的动物模型中使用的抗血管生成药物的完整综述见下表。
